Evaluation of Sustained/Controlled-Release Dosage Forms of 3-Hydroxy-3-methylglutaryl–Coenzyme A (HMG-CoA) Reductase Inhibitors in Dogs and Humans
作者： Haiyung Cheng , Steven C. Sutton , James D. Pipkin , Gaylen M. Zentner , J. Douglas Rogers
关键词:
摘要: Seven sustained/controlled-release dosage forms were designed for gastrointestinal delivery of lovastatin or simvastatin, two potent HMG-CoA reductase inhibitors the treatment hypercholesterolemia. The in vivo performance these formulations was evaluated dogs and healthy volunteers terms cholesterol lowering efficacy and/or systemic concentrations inhibitors. Results from present previous studies suggest that, through controlled release inhibitors, sustained lower plasma may result an equal better therapeutic efficacy.
springer.com
sci-hub.se 参考文章(10)
Gregory A. McClelland, R. John Stubbs, Joseph A. Fix, Stefano A. Pogany, Gaylen M. Zentner, Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form. Pharmaceutical Research. ,vol. 8, pp. 873- 876 ,(1991) , 10.1023/A:1015899328105
S Vickers, R A Halpin, I W Chen, D E Duggan, M S Schwartz, C A Duncan, W F Bayne, R J Stubbs, The physiological disposition of lovastatin. Drug Metabolism and Disposition. ,vol. 17, pp. 166- 173 ,(1989)
S Vickers, C A Duncan, A Rosegay, I W Chen, D E Duggan, Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metabolism and Disposition. ,vol. 18, pp. 138- 145 ,(1990)
Charles C Allain, Lucy S Poon, Cicely S G Chan, W Richmond, Paul C Fu, Enzymatic determination of total serum cholesterol. Clinical Chemistry. ,vol. 20, pp. 470- 475 ,(1974) , 10.1093/CLINCHEM/20.4.470
KV Ranga Rao, K Padmalatha Devi, None, Swelling controlled-release systems: recent developments and applications International Journal of Pharmaceutics. ,vol. 48, pp. 1- 13 ,(1988) , 10.1016/0378-5173(88)90245-1
Gaylen M. Zentner, Gerald S. Rork, Kenneth J. Himmelstein, The controlled porosity osmotic pump Journal of Controlled Release. ,vol. 1, pp. 269- 282 ,(1985) , 10.1016/0168-3659(85)90003-3
R. J. Stubbs, M. S. Schwartz, R. J. Gerson, T. J. Thornton, W. F. Bayne, Comparison of Plasma Profiles of Lovastatin (Mevinolin), Simvastatin (Epistatin) and Pravastatin (Eptastatin) in the Dog Drug Investigation. ,vol. 2, pp. 18- 28 ,(1990) , 10.1007/BF03258190
W. F. Hoffman, A. W. Alberts, P. S. Anderson, J. S. Chen, R. L. Smith, A. K. Willard, 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. Journal of Medicinal Chemistry. ,vol. 29, pp. 849- 852 ,(1986) , 10.1021/JM00155A040
Reagan H Bradford, Charles L Shear, Athanassios N Chremos, Carlos Dujovne, Maria Downton, Frank A Franklin, A Lawrence Gould, Michael Hesney, Jim Higgins, Dennis P Hurley, Alexandra Langendorfer, David T Nash, James L Pool, Harold Schnaper, None, Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia Archives of Internal Medicine. ,vol. 151, pp. 43- 49 ,(1991) , 10.1001/ARCHINTE.151.1.43
A. W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, E. Harris, A. Patchett, R. Monaghan, S. Currie, E. Stapley, G. Albers-Schonberg, O. Hensens, J. Hirshfield, K. Hoogsteen, J. Liesch, J. Springer, Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 77, pp. 3957- 3961 ,(1980) , 10.1073/PNAS.77.7.3957